Galectin Therapeutics (GALT)

• Market cap: $329M
• 1 day: -0.58%
• 5 days: 2.82%
• 1 month: 21.09%
• 3 months: 54.85%
• 6 months: 308.8%
• Year to date: 336.75%
• 1 year: 100.39%
• 5 years: 95.79%
• 10 years: 78.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 15